Regeneron Pharmaceuticals, Inc. reported a stellar quarter, with earnings hitting $12.89 per share, crushing the $8.43 expected by analysts. Citizens Financial Group Inc. RI reduced its stake in the ...

Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Study Overview: Regeneron Pharmaceuticals is conducting a ...

This clinical study could significantly impact Regeneron and Intellia’s stock performance by showcasing their capabilities in gene therapy. Positive outcomes may enhance investor confidence and ...

President Donald Trump has called on 17 pharmaceutical companies to implement most-favored-nation drug pricing in the next 60 days.

One of the companies mentioned in the letter is Regeneron Pharmaceuticals Inc. (NASDAQ:REGN). Regeneron Pharmaceuticals Inc. ...

The biotechnology industry is split between two very different types of companies. On one side are the large, blue-chip leaders like Amgen Inc. (ticker: AMGN), Gilead Sciences Inc.

Swiss National Bank trimmed its stake in Regeneron Pharmaceuticals, Inc. by a modest 0.5%. Despite this, Regeneron's share ...

Sanofi (SNY) halts shipments of cholesterol drug Praluent developed with Regeneron (REGN) due to availability issues. Read ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is one of the top most undervalued biotech stocks to buy now. Guggenheim ...

Sanofi said on Tuesday it had stopped supplying Praluent, a popular cholesterol drug jointly developed by the French ...

Moving on, Regeneron’s second-quarter report was largely positive. Total revenues of $3.68 billion (up 4% YoY) beat analyst ...

Regeneron Court Permits Government to Pursue False Certification Theory - On August 4, the district court in the closely ...